Search results
Merck & Co., Inc. (NYSE:MRK) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Simply Wall St. via Yahoo Finance· 11 hours agoMerck & Co., Inc. (NYSE:MRK) just released its quarterly report and things are looking bullish. The...
Analysts Set Merck & Co., Inc. (NYSE:MRK) Price Target at $131.25
ETF DAILY NEWS· 6 days agoMerck & Co., Inc. (NYSE:MRK – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently ...
Q3 2024 Earnings Forecast for Merck & Co., Inc. Issued By Leerink Partnrs (NYSE:MRK)
ETF DAILY NEWS· 6 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) – Research analysts at Leerink Partnrs raised their Q3 2024 earnings per share estimates for Merck< ...
Merck&Co earnings beat by $0.14, revenue topped estimates
Investing.com· 3 days agoMerck&Co earnings beat by $0.14, revenue topped estimates
Here’s Why Merck & Co. (MRK) Outperformed in Q1
Insider Monkey via Yahoo Finance· 4 days agoBaron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be...
Merck’s first-quarter results beat expectations amid healthy vaccine-sales growth
Market Watch· 3 days agoMerck & Co. Inc. on Thursday reported first-quarter results that beat analysts’ expectations amid...
Analysts review Merck & Co Inc’s rating – Knox Daily
Knox Daily· 6 days agoMerck & Co Inc’s recent filing unveils that its 10% Owner Merck & Co., Inc. acquired Company’s shares for reported ...
What Direction Does Merck & Co Inc (NYSE: MRK) Analysts Think The Company Will Take? – Stocks...
Stocks Register· 4 days agoThe trading price of Merck & Co Inc (NYSE:MRK) remained unchanged on Tuesday, April 23, closing at $126.88. The company’s P/E ratio in the trailing 12-month ...
Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
Proactive Investors· 3 days agoMerck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after...
Merck Raises Forecast as Sales of Its Cancer Immune Therapy Soar
Bloomberg· 3 days agoMerck & Co. raised its annual profit and revenue forecast as the blockbuster cancer drug Keytruda...